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Brody Recognized for Promising Pancreatic Cancer Research
Assistant Professor Jonathan Brody, PhD, has received a prestigious Career Development Award from the
Pancreatic Cancer Action Network (PanCAN) and the American Association for Cancer Research (AACR)
for his innovative research in pancreatic cancer.
One of three Career Development Awards granted to junior faculty at academic and medical institutions each
year, Dr. Brody’s award is named for the philanthropist and Rydex Investments founder Skip Viragh, who died
of pancreatic cancer in 2003. Dr. Brody accepted the award at a formal ceremony held on April 20 at the
annual meeting of the AACR in Washington, DC. He will receive $200K over the next two years.
“While the need for scientific and medical breakthroughs in pancreatic cancer research is urgent, there is a
major shortage of federal funding for research on this deadly disease,” says Julie Fleshman, President and CEO
of PanCAN. “Since 1999, PanCAN has been working to help fill this critical void. In 2010, we will disburse
nearly $2.3 million in funding for research grants. We are excited about this partnership with Dr. Brody and
look forward to working with him as we make strides against this deadly disease.”
Dr. Brody will use the funding to build upon his research on a stress-response protein called Hu antigen R
(HuR), “activated” in pancreatic tumor cells. Dr. Brody and his team have found that HuR can actually be used
to predict the effectiveness of the standard chemotherapy treatment for pancreatic cancer: gemcitabine.
“This means that HuR is essentially a biomarker, which we can use to determine up front whether a patient is
likely to respond to this treatment or not,” says Dr. Brody. The findings of his initial study, of which Dr. Brody
was the senior author and Jefferson pathologist Dr. Agnieszka Witkiewicz closely collaborated on, were first
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published as a Priority Report in the journal Cancer Research in June 2009. A follow up report is being
presented this month at the American Surgical Association in Chicago.
“By improving our understanding of drug metabolism and the molecular diversity that exists within the
patient population, this study has important implications for the development of personalized medicine for
pancreatic cancer,” notes Ms. Fleshman. “The results have the potential to help us learn how to customize
treatments for patients to improve outcomes and survival.”
Dr. Brody and his team are now seeking a way to activate HuR in patients that show low levels of the protein.
“The research is moving into expanding our clinical samples as well as building on pre-clinical animal models
for further exploration,” says Dr. Brody. “We are intrigued as to whether other chemotherapeutic agents might
also engage this same pathway.”
“As a young pancreatic cancer researcher I have always admired these two topnotch organizations,” says Dr.
Brody, “and to be recognized by them truly is an honor and validates the direction of my research.” This award
allows him to produce a body of high-quality data over the next few years as he strives to extend his funding
and work with the aid of such agencies as the National Cancer Institute (NCI). Ultimately, Dr. Brody hopes
this funding will help translate the work in his laboratory for the benefit of pancreatic cancer patients in the
clinical setting.
[Editor’s note: Dr. Brody has, as of this writing, just been notified that he has been awarded an American
Cancer Society grant in excess of $700k over the next 4 years.]
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Progress…Service Lines
Many in the Department have been involved 
with our institutional efforts initiating five 
robust service lines here at Jefferson. 
These service lines are co-directed by a 
physician and an administrator, supported 
by Executive Committees and Working 
Committees, and focused upon five specific 
areas of clinical activity:  
• Cancer
• Cardiovascular
• GI/Transplant
• Neurology/Neurosurgery
• Musculoskeletal
Our surgeons touch each of these areas, 
serve on their committees, and have helped 
direct initiatives dealing with quality and 
outcomes, growth of services, recruitments, 
marketing, etc. These service lines cross the 
traditional departmental silos, bring together 
physicians, surgeons and administrators 
who are focused on care in the given clinical 
areas, and have proved, even early in 
their existence, to be valuable as we look 
to grow, expand our imprint, and prepare 
for Jefferson’s medicine of the future. 
Of note, these service lines also provide 
opportunities for focused multidisciplinary 
training of our residents, students and 
fellows…in one of the five clinical areas 
mentioned above.
Additionally, a sixth, more “informal” service 
line deals with the Multidisciplinary Center 
for Critical Care. Recently new critical care 
beds have been built both at the Jefferson 
Hospital of Neuroscience (JHN) and on the 
4th floor of the Gibbon Building, ushering in 
a more robust opportunity for us to care for 
the increasingly ill and complex patients that 
are being treated here. As Thomas Jefferson 
said in 1810, “As new discoveries are 
made…institutions must advance also, and 
keep pace with the times.” 
Boy, are there changes afoot!
In a few short months, the Jefferson Breast 
Care Center has already distinguished 
itself nationally. Formally launched on 
October 1, 2009, with the appointment  
of Gordon Schwartz, MD, MBA, FACS  
as Center Director, the Center also 
received a full, 3-year accreditation from 
the National Accreditation Program for 
Breast Care Centers (NABCC) after a 
rigorous evaluation. 
The Center offers a unique approach to 
the care of any woman with questions 
related to breast health. “We want to 
serve people with specific diagnoses, but 
also strengthen our commitment to those 
whom we call ‘the worried well’,” says  
Dr. Schwartz, a Professor of Surgery.
The Center’s multidisciplinary approach 
integrates surgery, medicine, oncology, 
and radiation oncology, as well as 
integrative (and holistic) medicine and 
emotional support for women and their 
families. The Jefferson model coordinates 
and streamlines the process for patients, 
to avoid what one patient described as her 
experience elsewhere of “being treated by 
4 or 5 subcontractors, when what I really 
wanted was a general contractor.” 
The team of Jefferson specialists includes 
the new Assistant Director, Sun Yong 
Lee, MD, FACS who completed a breast 
The New Breast Care  
Center: Truly “Managed  
Care” for Women
Center director Gordon Schwartz, MD, MBA, FACS and assistant director Sun Yong (Sunny) 
Lee, MD, FACS lead the multidisciplinary team of the new Jefferson Breast Care Center.
Overview Clinical Integration
Joyce Hartmann, Physician Liaison 
for Liver Transplant Program
This fall marked the 25th anniversary  
of the region’s first liver transplant – 
performed at Jefferson – and since then, 
Joyce Hartmann has had the opportunity 
to represent Jefferson’s Liver Transplant 
Program to referring physicians throughout 
the Delaware Valley. 
With 20 years of healthcare marketing  
and program development experience, 
Joyce was attracted to the position 
because of the chance to represent the 
multidisciplinary team of physicians  
and surgeons, transplant coordinators, 
social workers and support staff. 
Jefferson’s Liver Transplant Program 
consistently surpasses national averages 
for transplantation survival rates,” Joyce 
explains. “Our surgeons transplant the 
sickest patients in the region and our 
program has the lowest mortality rate 
among patients on the recipient waiting list. 
It is a privilege to represent the team, to 
Please Welcome
ensure that their talents are known to referring 
physicians and patients receive the care that 
they need.”
To coordinate an office visit and for  
assistance with patient navigation or  
scheduling an appointment, please  
contact Joyce at 215-503-7507 or 
joyce.hartmann@jeffersonhospital.org. 
For more information about the  
Liver Transplant Program visit:  
www.jeffersonhospital.org/transplant/liver
surgery fellowship at Jefferson; Pramila 
Anné, MD, Associate Professor of 
Radiation Oncology; Neal Flomenberg, 
MD, Chair of Medical Oncology; and 
Barbara Cavanaugh, MD, Clinical 
Associate Professor of Radiology, in 
Breast Imaging. Other critical team 
members are administrator Rosanne 
Iacono, RN-C, MSN, CRNP, and 
coordinator Rita Battaglini, RN, BSN, 
who helps patients navigate the complex 
insurance system. 
Dr. Schwartz is committed to making 
the most of what scientists are doing 
across campus, “by integrating basic 
science results into our practice as soon 
as possible.” The Center will also have an 
international board of advisors, including 
the world-renowned Italian breast cancer 
surgeon Umberto Veronesi, MD, and 
others from Italy, France and the United 
Kingdom, making Jefferson a site for 
international collaboration.
The long-term plan for the center is to 
expand upon the Breast Imaging Center 
on the 4th floor of the Medical Office 
Building at 11th and Walnut Streets in 
Center City by adding a clinical facility 
one floor below. From its leadership to 
individual technicians, the Center staff 
strives to serve as a lifelong family for its 
patients. “The women we treat will have a 
home with us forever,” says Dr. Schwartz.
For more information about the Breast Care 
Center visit: www.jeffersonhospital.org/breast
Brody Recognized for Promising 
Pancreatic Cancer Research
Assistant Professor Jonathan Brody, 
PhD, has received a prestigious Career 
Development Award from the Pancreatic 
Cancer Action Network (PanCAN) and 
the American Association for Cancer 
Research (AACR) for his innovative 
research in pancreatic cancer. 
One of three Career Development Awards 
granted to junior faculty at academic and 
medical institutions each year, Dr. Brody’s 
award is named for the philanthropist and 
Rydex Investments founder Skip Viragh, 
who died of pancreatic cancer in 2003. 
Dr. Brody accepted the award at a formal 
ceremony held on April 20 at the annual 
meeting of the AACR in Washington, 
DC. He will receive $200K over the next 
two years.
“While the need for scientific and 
medical breakthroughs in pancreatic 
cancer research is urgent, there is a 
major shortage of federal funding for 
research on this deadly disease,” says 
Julie Fleshman, President and CEO of 
PanCAN. “Since 1999, PanCAN has been 
working to help fill this critical void. In 
2010, we will disburse nearly $2.3 million 
in funding for research grants. We are 
excited about this partnership with  
Dr. Brody and look forward to working 
with him as we make strides against  
this deadly disease.”
Dr. Brody will use the funding to build 
upon his research on a stress-response 
protein called Hu antigen R (HuR), 
“activated” in pancreatic tumor cells. 
Dr. Brody and his team have found 
that HuR can actually be used to 
predict the effectiveness of the standard 
chemotherapy treatment for pancreatic 
cancer: gemcitabine.
“This means that HuR is essentially 
a biomarker, which we can use to 
determine up front whether a patient is 
likely to respond to this treatment or not,” 
says Dr. Brody. The findings of his initial 
study, of which Dr. Brody was the senior 
author and Jefferson pathologist Dr. 
Agnieszka Witkiewicz closely collaborated 
on, were first published as a Priority 
Report in the journal Cancer Research in 
June 2009. A follow up report is being 
presented this month at the American 
Surgical Association in Chicago.  
“By improving our understanding of 
drug metabolism and the molecular 
diversity that exists within the patient 
population, this study has important 
implications for the development of 
personalized medicine for pancreatic 
cancer,” notes Ms. Fleshman. “The results 
have the potential to help us learn how 
to customize treatments for patients to 
improve outcomes and survival.” 
Dr. Brody and his team are now seeking a 
way to activate HuR in patients that show 
low levels of the protein. “The research 
is moving into expanding our clinical 
samples as well as building on pre-clinical 
animal models for further exploration,” 
says Dr. Brody. “We are intrigued as to 
whether other chemotherapeutic agents 
might also engage this same pathway.” 
“As a young pancreatic cancer researcher 
I have always admired these two top-
notch organizations,” says Dr. Brody, 
“and to be recognized by them truly is 
an honor and validates the direction of 
my research.” This award allows him to 
produce a body of high-quality data over 
the next few years as he strives to extend 
his funding and work with the aid of such 
agencies as the National Cancer Institute 
(NCI). Ultimately, Dr. Brody hopes this 
funding will help translate the work in his 
laboratory for the benefit of pancreatic 
cancer patients in the clinical setting. 
[Editor’s note: Dr. Brody has, as of this 
writing, just been notified that he has  
been awarded an American Cancer Society 
grant in excess of $700k over the next  
4 years.]
Katie Ashburn, CRNP,  
and Shawn Pierce, CNRP, 
are Vascular Surgery Nurse Practitioners 
for the outpatient and inpatient practices 
(respectively). They both assumed their 
positions in late spring of 2009.
What does an average day look like?
Katie: Between the vascular attending 
physicians and me, we see 40 patients 
a day in a fast-paced outpatient office. 
I perform patient history and physicals 
and develop a plan of care in conjunction 
with the attendings, to improve patient 
education and communication. I follow 
wound care patients and occasionally 
manage insurance issues. We work closely 
with the anticoagulation clinic and the 
hyperbaric treatment center. 
Shawn: I work with the vascular team 
comprised of an intern, a resident, a 
fellow and Drs. Paul DiMuzio and Joshua 
Eisenberg. Together we manage patients 
in surgery as well as on the floor. I work 
closely with our case manager on more 
complicated discharge cases. After 
patients leave, I call to help with questions 
or complications. 
What are your respective backgrounds?
Katie: I worked as a nurse at Jefferson for 
5 years, including the Intermediate Surgical 
Intensive Care Unit for 18 months and the 
Surgical Intensive Care Unit for 3½ years. 
I earned my master’s degree at Jefferson 
during that time.
Shawn: I have been a nurse for 23 years 
and I taught for 10, so many of the nurses 
here know me as an instructor. I worked 
as a critical care “float” RN working in 
the Intensive Care Units and the Post 
Anesthesia Care Unit as needed. 
Do the two of you work together?
Shawn: We share an office and often 
confer with each other to improve 
continuity in patient care. Patients 
appreciate how well we know them.
Jonathan Brody, PhD, and his team of technicians, residents and students are  
conducting studies that are garnering financial support for a historically underfunded  
field of research – pancreatic cancer.
For an appointment with a Jefferson Surgeon, call 1-800-JEFF-NOW
Changing Lives Through Research On the Job
“The results have the 
potential to help us 
learn how to customize 
treatments for patients  
to improve outcomes  
and survival.” “We want to serve people 
with specific diagnoses, 
but also strengthen  
our commitment to  
those whom we call  
‘the worried well’”
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